	US 11,793,851 B2
	Method for treating a side effect caused by BCG perfusion therapy for bladder cancer
Hsuan-Ching Tseng, New Taipei (TW); Da-Tong Ju, Taipei (TW); Sung-Sen Yang, Taipei (TW); Wei-Te Cheng, New Taipei (TW); Chen-Yu Lee, Taipei (TW); and Yan-Chih Liao, Taipei (TW)
Assigned to Chen-Yu Lee, Taipei (TW)
Filed by Chen-Yu Lee, Taipei (TW)
Filed on Sep. 3, 2020, as Appl. No. 17/10,883.
Prior Publication US 2022/0062364 A1, Mar. 3, 2022
Int. Cl. A61K 36/515 (2006.01); A61P 1/14 (2006.01); A61K 36/744 (2006.01); A61K 36/232 (2006.01); A61K 36/64 (2006.01); A61K 36/71 (2006.01); A61K 36/233 (2006.01); A61K 36/68 (2006.01); A61K 36/284 (2006.01); A61K 36/884 (2006.01); A61K 36/484 (2006.01); A61K 36/899 (2006.01); A61K 36/65 (2006.01); A61K 36/488 (2006.01); A61K 36/708 (2006.01); A61K 36/734 (2006.01); A61K 35/57 (2015.01); A61P 13/10 (2006.01); A61P 13/02 (2006.01); A61P 25/00 (2006.01); A61K 36/539 (2006.01)

CPC A61K 36/515 (2013.01) [A61K 35/57 (2013.01); A61K 36/232 (2013.01); A61K 36/233 (2013.01); A61K 36/284 (2013.01); A61K 36/484 (2013.01); A61K 36/488 (2013.01); A61K 36/539 (2013.01); A61K 36/64 (2013.01); A61K 36/65 (2013.01); A61K 36/68 (2013.01); A61K 36/708 (2013.01); A61K 36/71 (2013.01); A61K 36/734 (2013.01); A61K 36/744 (2013.01); A61K 36/884 (2013.01); A61K 36/899 (2013.01); A61P 1/14 (2018.01); A61P 13/02 (2018.01); A61P 13/10 (2018.01); A61P 25/00 (2018.01)]

21 Claims

1. A method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer, comprising:

administering a Chinese medicine composition to a subject in need thereof;

wherein, the Chinese medicine composition is an extract of a first mixture consisting of Gentiana scabra, Scutellariae Radix, Gardeniae Fructus, Angelicae Sinensis Radix, Rehmanniae radix, Akebiae Caulis, Bupleurum chinense, Plantaginis Semen, Atractylodes lancea, Rhizoma alismatis, Glycyrrhiza uralensis, and Typhae pollen.